Parvus Therapeutics Inc. is a privately-owned biopharmaceutical firm dedicated to developing Navacims™, a platform technology stemming from seminal research first detailed in 2016 (Nature 530:434), for the treatment of autoimmune disorders. Parvus is committed to reshaping treatment methods by focusing on Navacim-directed immune regulation, thereby circumventing the nonspecific immune suppression commonly associated with exi...
Parvus Therapeutics Inc. is a privately-owned biopharmaceutical firm dedicated to developing Navacims™, a platform technology stemming from seminal research first detailed in 2016 (Nature 530:434), for the treatment of autoimmune disorders. Parvus is committed to reshaping treatment methods by focusing on Navacim-directed immune regulation, thereby circumventing the nonspecific immune suppression commonly associated with existing therapies. Parvus is actively progressing a portfolio of proprietary drug candidates targeting various autoimmune indications from preclinical development to clinical stages.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.